Abstract
Pyrrolo[2,1-a]isoquinoline is a privileged bioactive scaffold, yet its conventional synthesis typically relies on metal catalysis or pre-functionalized substrates. Developing efficient, metal-free synthetic routes is therefore crucial from both green chemistry and practical application perspectives. In this work, we report a metal-free, acid-promoted cascade cyclization that efficiently affords diverse pyrrolo[2,1-a]isoquinolines in good to excellent yields under mild conditions. This one-pot strategy features operational simplicity, broad substrate scope, and scalability for gram-scale preparation. The resulting compounds serve as acceptor units for constructing thermally activated delayed fluorescence (TADF) materials with aggregation-induced emission (AIE) properties, thus opening a new pathway toward multifunctional organic luminescent materials. Notably, using this approach, we have developed two green-fluorescent materials with good biocompatibility. Without requiring nanocarriers, these materials are efficiently endocytosed into HeLa cells and enable effective bioimaging. Furthermore, upon light irradiation, they generate significant levels of reactive oxygen species and achieve photodynamic therapy of HeLa cells via a Type I mechanism.

Subject terms: Synthetic chemistry methodology, Optical materials
Pyrrolo[2,1-a]isoquinolines are attractive scaffolds for functional materials, but current approaches for their synthesis rely on pre-functionalized starting materials, metal catalysts, or complex photoredox systems, which can limit product diversity. Here, the authors report a one-pot, metal-free strategy based on acid-promoted cascade cyclization that features operational simplicity, broad substrate scope, and scalability for gram-scale preparation, and demonstrate its application in the preparation of green-fluorescent materials for bioimaging and photodynamic therapy.
Introduction
The pyrrolo[2,1-a]isoquinoline scaffold represents a privileged structural motif present in a wide range of bioactive natural products1–3, including crispine A and marine-derived lamellarin alkaloids4–6. This framework exhibits diverse pharmacological activities, such as antitumor effects7–10, reversal of multidrug resistance11, and antimicrobial properties12. Over the past decades, a variety of synthetic strategies have been developed for constructing the pyr-rolo[2,1-a]isoquinoline scaffold13–19. Among these, the 1,3-dipolar cycloaddition strategy has emerged as a particularly efficient approach, enabling assembly of the core framework with high stereoselectivity and regioselectivity14,15,20–22. However, current synthetic methodologies for pyrrolo[2,1-a]isoquinolines are predominantly based on two-component cycloaddition reactions involving pre-functionalized tetrahydroisoquinoline substrates bearing electron-withdrawing groups (Fig. 1b). These approaches typically rely on transition-metal catalysis23,24, photocatalysis25–28, or stoichiometric additives29–32 to generate the key ylide intermediate. While such methods have contributed significantly to the field, their dependence on pre-functionalized starting materials, metal catalysts, or complex photoredox systems can limit product diversity and overall greenness. In recent years, several multi-component metal-free protocols have emerged as valuable alternatives33,34. Nevertheless, many of these approaches still require pre-functionalized substrates, excess oxidants, or involve multistep sequences, which may constrain substrate scope, overall efficiency, and practical applicability. Nevertheless, the development of concise, metal-free, and environmentally benign synthetic routes to access this privileged scaffold remains valuable and desirable.
Fig. 1. A brief overview of pyrrolo[2,1-a]isoquinoline alkaloids and their cycloaddition strategies.

a Representative bioactive alkaloids. b Previously reported [3 + 2] cycloaddition pathway. c Reaction design and practical utility in this work.
Photodynamic therapy (PDT) represents a promising photo-chemical-based anticancer modality, offering excellent spatiotem-poral controllability, minimal invasiveness, and inherent tissue selectivity35–39. Based on the photosensitizer’s reaction pathway, PDT mechanisms are classified into type I and type II40–42. In conventional type II PDT, photoexcited photosensitizers undergo intersystem crossing (ISC) from the singlet to the triplet state, followed by energy transfer to ground-state oxygen (3O2) to generate highly cytotoxic singlet oxygen (1O2)43. In contrast, type I PDT proceeds via an electron transfer pathway, wherein the excited triplet-state photo-sensitizer interacts directly with surrounding biomolecules to yield highly reactive radical species, including superoxide anion (·O2⁻) and hydroxyl radical (·OH)44,45. Under the hypoxic conditions typical of solid tumors, type I photodynamic mechanisms demonstrate superior therapeutic potential46,47.
Thermally activated delayed fluorescence (TADF) materials are a class of purely organic emitters characterized by a minimal singlet–triplet energy gap (ΔEST)48–50. They offer unique advantages such as low cost, high luminescence efficiency, structural stability, and rich excited-state processes, rendering them highly applicable in organic light-emitting diodes51–54, photocatalytic synthesis55, bioimaging56, biosensing57, and nanomedicine58–60. Most TADF materials used in biomedicine and sensing are designed based on donor–acceptor (D–A) molecular architecture59,60. Developing acceptor units is essential to enrich the structural diversity of TADF molecular libraries and establish universal design strategies for advanced acceptor motifs.
Building on our prior work in metal-free pyrrolo[2,1-a]isoquinoline synthesis via the I2–DMSO–aryl methyl ketone system63–66, we herein report a one-pot, metal-free method to access these scaffolds from α-bromophenylethanones, 1,2,3,4-tetrahydroisoquinolines (THIQs), and electron-deficient alkenes. The reaction proceeds efficiently under mild conditions with air as the terminal oxidant, offering high atom economy, broad substrate scope, and practical scalability. The products function as versatile acceptor building blocks for constructing aggregation-induced emission (AIE)-active TADF materials. Moreover, we have developed an intrinsically fluorescent and biocompatible photosensitizer that enables self-delivering cellular uptake without nanocarriers, allowing integrated cellular imaging and type I photodynamic therapy.
Results and discussion
Transformation developments
In pursuit of an efficient and concise one-pot synthesis of pyrrolo[2,1-a]isoquinoline derivatives, we conducted a systematic screening of reaction parameters—including solvent, Brønsted acid identity and stoichiometry, and temperature (Suppl. Table S1 for details). Through screening a series of variables and conditions, we found that treating three commercially available materials: α-bromophenylethanones (1a), 1,2,3,4-tetrahydroisoquinoline (THIQ) (2a) and acrylonitrile (3a) with AcOH in a solution of DMF (0.2 M) at 80 oC in the air atmosphere for 6 h lead to the formation of the corresponding pyrrolo[2,1-a]isoquinolines (4a) in 73% yield (Suppl. Table S1, entry no. 15). These optimum conditions are recognized as our standard conditions in the following sections.
Synthesis of pyrrolo[2,1-a]isoquinolines by the reaction of α-bromophenylethanones, 1,2,3,4-tetrahydroisoquinolines, and electron-deficient alkenes
With the optimum conditions in hand, we proceeded to investigate the functional group tolerance of this transformation, and substrates bearing diverse substituents on the aromatic ring of α-bromophenylethanones were well tolerated in the reaction. As illustrated in Fig. 2, substrates with electron-donating groups (Me, iPr, OMe, 3,4-OCH2O, SMe) on the phenyl ring underwent smooth conversion, affording the target products in good yields (4b–4 g, 65–78%). Halogen-substituted substrates were subsequently examined, meta- and para-substituted variants delivered satisfactory results (4i–4p, 54%–89%), whereas ortho-bromo substitution led to a diminished yield (4 h, 25%), presumably due to steric constraints. Furthermore, substrates incorporating electron-withdrawing groups (NO2, CN, OCF3, CO2Me) were also well tolerated, providing the target products 4q–4 u in moderate to excellent yields (42%–83%). The scope was successfully extended to sterically hindered and heteroaromatic systems. Notably, thiophene-, pyridine-, benzofuran-, biphenyl-, and 2-naphthyl-functionalized substrates underwent efficient conversion, delivering products 4v–4z in excellent yields (75%–91%). (E)-1-bromo-4-phenylbut-3-en-2-one was also compatible, furnishing the target product 4aa in 56% yield. However, the 1-(bromoadamantyl) ketone substrate failed to produce the desired product under the standard conditions.
Fig. 2. Substrate scope of α-bromophenylethanones for the synthesis of pyrrolo[2,1-a]isoquinolines.

Reaction conditions: 1 (1.0 mmol, 1.0 equiv), 2a (1.0 mmol, 1.0 equiv), 3a (1.0 mmol, 1.0 equiv), AcOH (2.0 mmol, 2.0 equiv), DMF (5.0 mL, c = 0.2 M), 80 oC, air atmosphere. Isolated yield.
Subsequently, the substrate scope of THIQ derivatives was evaluated. As shown in Fig. 3, halogen substituents at various positions on the aromatic ring of THIQ demonstrated excellent reactivity (5a–5e, 70%–84%). THIQ derivatives bearing electron-donating (OMe) and electron-withdrawing (NO2) substituents afforded the target products in 74% yields (5f–5 g). It is noteworthy that isoquinoline and 1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indole are also compatible with this transformation, providing the target product in moderate to good yields (5h–5 m, 42%–83%). The structure of 5 l was confirmed by X-ray crystallography (CCDC: 2505511; Suppl. Fig. S1 and Suppl. Data 1). Furthermore, the effect of different electron-deficient alkenes was investigated, including methyl, tert-butyl, and n-butyl substituted acrylates, (E)-(2-nitrovinyl)benzene, (E)-2-(2-nitrovinyl)thiophen, N-methylmaleimide, as well as coumarin and naphthoquinone derivatives (Fig. 3). It is noteworthy that the nitro group in substrates such as (E)-(2-nitrovinyl)benzene and (E)-2-(2-nitrovinyl)thiophene was readily eliminated during the reaction, leading to the formation of products 6 f and 6 g with the nitro group removed. Pleasingly, all substrates delivered the desired products in excellent yields (6a–6k, 72–92%), further validating the broad scope and functional group tolerance of this methodology. Based on control experiments (Suppl. Fig. S2) and literature precedents27,61–64, a plausible reaction mechanism has been proposed (Suppl. Fig. S5). The process proceeds via acetic acid-promoted in situ generation of azomethine ylides (detected by HRMS, Suppl. Fig. S3–S4) from α-bromophenylethanones and THIQs, followed by a sequential 1,3-dipolar cycloaddition/aromatization cascade with electron-deficient alkenes to afforded the desired products.
Fig. 3. Substrate scope of THIQs and electron-deficient alkenes for the synthesis of pyrrolo[2,1-a]isoquinolines.

Reaction conditions: 1 (1.0 mmol, 1.0 equiv), 2 (1.0 mmol, 1.0 equiv), 3 (1.0 mmol, 1.0 equiv), AcOH (2.0 mmol, 2.0 equiv), DMF (5.0 mL, c = 0.2 M), 80 oC, air atmosphere. Isolated yield.
Study on the practicability of reactions
To demonstrate the practical utility of this synthetic strategy, we noted that compound 5k has been previously reported to exhibit significant antifungal activity32. Building on this finding, we scaled up the synthesis of this compound, successfully obtaining the target product in 61% isolated yield on a gram scale (Fig. 4a).
Fig. 4. The practicability of reactions.

a Scale-up experiment. b Modification strategy for photofunctional molecules. c Modification strategy for PDT molecules.
To our delight, the pyrrolo[2,1-a]isoquinoline scaffold can serve as an electron acceptor unit for constructing thermally activated delayed fluorescence materials with aggregation-induced emission properties. Halogen-substituted substrates (4j, 4 l, 4n) were functionalized with different electron donors—9H-carbazole (Cz), 3,6-dimethoxy-9H-carbazole (DMCz), 7H-benzo[c]carbazole (BCz), phenothiazine (PTZ), and 9,9-dimethyl-9,10-dihydroacridine (DMAC)—via base-promoted nucleophilic substitution or palladium-catalyzed coupling reactions to afford the target compounds 7–12. The synthetic route is illustrated in SI.
We first performed density functional theory (DFT) calculations to optimize the ground-state geometries of the molecules using the B3LYP-D3(BJ) functional and the 6-31 G(d) basis set. The calculated ΔEST values are small, particularly for compounds 10-12 ( < 0.02 eV), suggesting that these molecules may exhibit TADF properties (Supplementary Table S4). The UV-Vis absorption spectra and fluorescence spectra of these molecules in toluene are shown in Suppl. Fig. S6. All molecules showed distinct nanosecond-scale prompt fluorescence and microsecond-scale delayed fluorescence components (Fig. 5 and Suppl. Data 2). In steady-state photoluminescence measurements, argon degassing significantly increased the emission intensity (Suppl. Fig. S10). These results confirm the delayed fluorescence feature of these molecules. The photophysical data are summarized in Supp. Tables S3, S4. Additionally, in the THF/H₂O mixed system, the variation in luminescence intensity with the water fraction (fw) indicates that all three molecules possess distinct AIE characteristics (Suppl. Figs. S8, S9).
Fig. 5. Photophysical properties of compounds 7-12 in toluene solution.

a–f Normalized transient delayed fluorescence decay curves of compounds 7-12 in toluene solution. Inset: Normalized transient prompt fluorescence decay curves of compounds 7-12 in toluene solution.
To our surprise, the target compounds 5 l and 5 m, synthesized from α-bromophenylethanones, β-carboline, and (E)-(2-nitrovinyl)benzene, exhibit distinct luminescent properties. The UV-Vis absorption and fluorescence spectra of both molecules in THF solution are shown in Suppl. Fig. S11. To explore their potential biomedical applications, we first evaluated the biosafety of the compounds using mouse fibroblast (L929) cells via the cell counting kit-8 (CCK-8) assay (Fig. 6a, b and Suppl. Data 3), and the results indicated excellent biocompatibility. We then performed confocal fluorescence imaging of HeLa cells incubated with 5 l and 5 m. As illustrated in Fig. 6c, d, co-localization experiments with the nuclear dye Hoechst 33342 confirmed effective cellular internalization of both compounds, along with bright and stable green fluorescence emission.
Fig. 6. Biosafety and confocal fluorescence imaging applications of compounds 5 l and 5 m.

a, b Cell viability of L929 cells with varying concentrations of 5 l and 5 m using CCK-8 working solution (n = 3). c, d Confocal fluorescence and merged images of HeLa cells with 25 μM of 5 l and 5 m in DMEM medium (excitation: 488 nm, emission: 550–600 nm). The nuclei were stained with Hoechst 33342 (excitation: 330 nm, emission: 430–450 nm, scale bar: 8 μm).
We then investigated the reactive oxygen species (ROS) generation capability of these materials with the aim of developing them as theranostic fluorescent probes. First, 2′,7′-dichlorodihydrofluorescein diacetate (DCFH-DA) was employed as a fluorescent indicator to assess ROS production under light irradiation. As shown in Fig. 7a and Suppl. Fig. S12, the fluorescence intensity of DCFH-DA alone remained nearly unchanged under irradiation. In contrast, in the presence of 5 m or 5 l, a time-dependent increase in fluorescence intensity at 525 nm was observed, reaching over 500-folds enhancement compared to the probe control. This clearly demonstrates the remarkable ROS-generation capability of the compounds. We further utilized dihydrorhodamine 123 (DHR123), hydroxyphenyl fluorescein (HPF), and 9,10-anthracenediyl-bis(methylene)dimalonic acid (ABDA) as specific probes to detect O2•⁻, •OH, and 1O2, respectively, with the commercial type II photosensitizer chlorine6 (Ce6) serving as a control. As illustrated in Fig. 7b–d and Suppl. Figs. S13–S15, compounds 5 l and 5 m were demonstrated to efficiently generate O2•⁻ and •OH through a type-I photodynamic pathway upon photoactivation, while producing negligible 1O2. Specifically, DHR123 and HPF assays revealed rapid fluorescence enhancement upon irradiation, indicating substantial formation of O2•⁻ and an 11-fold increase in •OH generation, respectively. In contrast, ABDA degradation assays confirmed minimal 1O2 production. These findings establish compounds 5 l and 5 m as promising type-I photosensitizers, highlighting their strong potential for PDT applications.
Fig. 7. Evaluation of the ROS generation and cytotoxicity of compounds 5 l and 5 m under light and dark conditions.

Changes in relative emission intensities of (a) DCFH-DA, (b) DHR 123 and (c) HPF in the three systems under laser irradiation (white light, 1 W cm−2). Plots of absorbance of (d) ABDA at 378 nm for photodegradation rate detection in the four systems. Cell viability of HeLa cells with varying concentrations of (e) 5 l, (f) 5 l NPs, (g) 5 m, (h) 5 m NPs using CCK-8 working solution (n = 3) under non-irradiation and irradiation conditions (white light, 1 W cm−2).
Encouraged by these results, we evaluated the cytotoxicity under both light and dark conditions using the CCK-8 assay in HeLa cells. To address the water solubility of the pure organic compounds, we prepared nanoparticle formulations (designated 5 l NPs and 5 m NPs) using DSPE-PEG2000 and NH2-PEG-FA to improve biocompatibility. As shown in Fig. 7e–h, both compounds showed negligible effects on cell viability in the dark. In contrast, light irradiation induced a concentration-dependent decrease in cell viability. At equivalent concentrations, 5 l NPs and 5 m NPs exhibited stronger photoinduced antitumor efficacy than the pure compounds, which can likely be attributed to enhanced cellular uptake.
Conclusions
In summary, this work establishes a metal-free strategy for synthesizing pyrrolo[2,1-a]isoquinolines from readily available starting materials under mild conditions with broad substrate compatibility. The protocol demonstrates significant practical utility, enabling scalable one-step construction of antifungal frameworks in 61% yield. Furthermore, the resulting scaffold functions as an efficient electron-acceptor unit for high-performance AIE-TADF emitters and allows direct assembly of self-deliverable photosensitizers that integrate bioimaging with type-I photodynamic therapy. Future studies will expand the applications of this privileged heterocyclic architecture in pharmaceutical and materials science research.
Methods
α-bromophenylethanone 1a (199.1 mg, 1.0 mmol), 1,2,3,4-tetrahydroisoquinoline 2a (133.1 mg, 1.0 mmol), acrylonitrile 3a (53.1 mg, 1.0 mmol), acetic acid (120.1 mg, 2.0 mmol) and DMF (5.0 mL, c 0.2 M), and the resulting mixture was stirred at 80 °C (heating block) for 6 h until substrate conversion was almost complete by TLC analysis. After the reaction stopped and cooled at room temperature, the reaction mixture was quenched with saturated Na2CO3 solution (100 mL). The aqueous layer was extracted with ethyl acetate (EtOAc, 3 × 100 mL), and the organic layers were separated and merged. The mixture was dried with anhydrous Na2SO4 and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel (200–mesh, eluted with petroleum ether/EtOAc = 10:1) to afford the product 4a.
Supplementary information
Description of Additional Supplementary Files
Author contributions
K.Z. and A.W. conceived the study. J.H., J.G., X.L., L.C., M.S. and H.Z. synthesized and characterized the materials. J.H. and M.W. measured the photophysical property, bioimaging, and PDT applications. K.Z., J.H. and X.Y. drafted the paper. All authors discussed the results and contributed to the preparation of the paper.
Peer review
Peer review information
Communications Chemistry thanks Moumita Gangopadhyay and Youhei Takeda for their contribution to the peer review of this work. A peer review file is available.
Funding
This work was supported by the National Natural Science Foundation of China (Grant No. 22405062). This work was also supported by the State Key Laboratory of Pathogenesis, Prevention, Treatment of Central Asian High Incidence Diseases Fund (SKL-HIDCA-2025-GD6), the Clinical & Basic Science Technology Innovation Project of Guangdong Medical University (GDMULCJC2025250), Funds for Ph.D. Researchers of Guangdong Medical University in 2025 (4SG25007G), and the Guangdong Medical University Undergraduate Innovation and Entrepreneurship Education Base Project (2JD24014, JDXM2024189).
Data availability
The X-ray crystallographic coordinates for structures reported in this article have been deposited at the Cambridge Crystallographic Data Centre (CCDC), under deposition numbers CCDC 2505511. These data can be obtained free of charge from either Supplementary Data 1 or The Cambridge Crystallographic Data Center via https://www.ccdc.cam.ac.uk/ structures/. Source data for ROS generation and cytotoxicity assays (light/dark) are provided in Supplementary Data 4. NMR spectra for all synthesized compounds are provided in Supplementary Data 5. All other data supporting the findings of the study, including experimental procedures and compound characterization, UV–vis absorption spectrometry, fluorescence and phosphorescence spectrometry, are available within the paper and the Supplementary Information. Correspondence and requests for materials should be addressed to K.L.Z.; all data are available from the corresponding author upon request.
Competing interests
The authors declare no competing interests.
Footnotes
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Contributor Information
Anxin Wu, Email: chwuax@mail.ccnu.edu.cn.
Xuemei Yang, Email: Yangxm@gdmu.edu.cn.
Kailu Zheng, Email: kailuzheng@gdmu.edu.cn.
Supplementary information
The online version contains supplementary material available at https://doi.org/10.1038/s42004-026-02133-0.
References
- 1.Balewski, Ł & Kornicka, A. Recent advances in synthetic isoquinoline-based derivatives in drug design. Molecules30, 4760 (2025). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Li, Q., Han, L., Zhou, H., Hou, J. & Shi, X. Advances in synthetic strategies for indolo[2,1-a]isoquinoline derivatives. Adv. Synth. Catal.367, e202500035 (2025). [Google Scholar]
- 3.Krishnaiah, P. et al. New lamellarin alkaloids from the indian ascidian didemnum obscurum and their antioxidant properties. J. Nat. Prod.67, 1168–1171 (2004). [DOI] [PubMed] [Google Scholar]
- 4.Fan, H., Peng, J., Hamann, M. T. & Hu, J.-F. Lamellarins and related pyrrole-derived alkaloids from marine organisms. Chem. Rev.108, 264–287 (2008). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Mohan, C., Krishna, R. B., Sivanandan, S. T. & Ibnusaud, I. Synthesis of pyrrolo[2,1-a]isoquinoline class of natural product crispine A. Eur. J. Org. Chem.2021, 4911–4926 (2021). [Google Scholar]
- 6.Wei, M. et al. Progress on synthesis and structure-activity relationships of lamellarins over the past decade. Eur. J. Med. Chem.269, 116294 (2024). [DOI] [PubMed] [Google Scholar]
- 7.Bailly, C. Anticancer properties of lamellarins. Mar. Drugs. 13, 1105 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.García Maza, L. J., Salgado, A. M., Kouznetsov, V. V. & Meléndez, C. M. Pyrrolo[2,1-a]isoquinoline scaffolds for developing anti-cancer agents. RSC Adv.14, 1710–1728 (2024). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Tardy, C. et al. Topoisomerase I-mediated DNA cleavage as a guide to the development of antitumor agents derived from the marine alkaloid lamellarin D: triester derivatives incorporating amino acid residues. Bioorg. Med. Chem.12, 1697–1712 (2004). [DOI] [PubMed] [Google Scholar]
- 10.Baunbæk, D. et al. Anticancer alkaloid lamellarins inhibit protein kinases. Mar. Drugs. 6, 514 (2008). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Salehian, F. et al. A review: biologically active 3,4-heterocycle-fused coumarins. Eur. J. Med. Chem.212, 113034 (2021). [DOI] [PubMed] [Google Scholar]
- 12.Hazra, A. et al. Amberlite–IRA-402 (OH) ion exchange resin mediated synthesis of indolizines, pyrrolo[1,2-a]quinolines and isoquinolines: antibacterial and antifungal evaluation of the products. Eur. J. Med. Chem.46, 2132–2140 (2011). [DOI] [PubMed] [Google Scholar]
- 13.Seidel, D. The azomethine ylide route to amine C–H functionalization: redox-versions of classic reactions and a pathway to new transformations. Acc. Chem. Res.48, 317–328 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Cui, H.-L. Recent progress in the synthesis of pyrrolo[2,1-a]isoquinolines. Org. Biomol. Chem.20, 2779–2801 (2022). [DOI] [PubMed] [Google Scholar]
- 15.Bera, S. et al. Recent advances in the synthesis of chromenone fused pyrrolo[2,1-a]isoquinoline derivatives. N. J. Chem.47, 22246–22268 (2023). [Google Scholar]
- 16.Ploypradith, P., Mahidol, C., Sahakitpichan, P., Wongbundit, S. & Ruchirawat, S. A highly efficient synthesis of lamellarins K and L by the Michael addition/ring-closure reaction of benzyldihydroisoquinoline derivatives with ethoxycarbonyl-β-nitrostyrenes. Angew. Chem. Int. Ed.43, 866–868 (2004). [DOI] [PubMed] [Google Scholar]
- 17.Su, S. & Porco, J. A. Synthesis of pyrrolo-isoquinolines related to the lamellarins using silver-catalyzed cycloisomerization/dipolar cycloaddition. J. Am. Chem. Soc.129, 7744–7745 (2007). [DOI] [PubMed] [Google Scholar]
- 18.Ueda, K., Amaike, K., Maceiczyk, R. M., Itami, K. & Yamaguchi, J. -Selective C–H arylation of pyrroles leading to concise syntheses of lamellarins C and I. J. Am. Chem. Soc.136, 13226–13232 (2014). [DOI] [PubMed] [Google Scholar]
- 19.Wu, L., Sun, J. & Yan, C. Efficient synthesis of pyrrolo[2,1-a]isoquinoline and pyrrolo[1,2-a]quinoline derivatives via one-pot two-step metal-catalyzed three-component reactions. Chin. J. Chem.30, 590–596 (2012). [Google Scholar]
- 20.Xi, W. et al. Synthesis of fluorinated pyrrolo[2,1-a]isoquinolines through decarboxylative/dehydrofluorinative [3 + 2] cycloaddition aromatization of isoquinolinium N-ylides with difluoroenoxysilanes. Org. Lett.25, 4908–4912 (2023). [DOI] [PubMed] [Google Scholar]
- 21.Li, Y.-G. et al. Pd/C-catalyzed dehydrogenative [3 + 2] cycloaddition for the synthesis of dihydropyrrolo[2,1-a]isoquinolines. J. Org. Chem.90, 7995–7999 (2025). [DOI] [PubMed] [Google Scholar]
- 22.Shang, Z.-H. et al. One-Pot Synthesis of Chromone-Fused Pyrrolo[2,1-a]isoquinolines and Indolizino[8,7-b]indoles: Iodine-Promoted Oxidative [2 + 2 + 1] Annulation of O-Acetylphenoxyacrylates with Tetrahydroisoquinolines and Noreleagnines. J. Org. Chem.86, 15733–15742 (2021). [DOI] [PubMed] [Google Scholar]
- 23.Yu, C., Zhang, Y., Zhang, S., Li, H. & Wang, W. Cu(ii) catalyzed oxidation-[3+2] cycloaddition-aromatization cascade: efficient synthesis of pyrrolo[2,1-a] isoquinolines. Chem. Commun.47, 1036–1038 (2011). [DOI] [PubMed] [Google Scholar]
- 24.Cui, H.-L. & Chen, X.-H. Synthesis of pyrrolo[2,1-a]isoquinolines through Cu-catalyzed condensation/addition/oxidation/cyclization cascade. J. Org. Chem.87, 15435–15447 (2022). [DOI] [PubMed] [Google Scholar]
- 25.Zou, Y.-Q. et al. Visible-light-induced oxidation/[3+2] cycloaddition/oxidative aromatization sequence: a photocatalytic strategy to construct pyrrolo[2,1-a]isoquinolines. Angew. Chem. Int. Ed.50, 7171–7175 (2011). [DOI] [PubMed] [Google Scholar]
- 26.Liu, Y., Shen, L., Yang, H., Zhao, X. & Lan, X. A dual-engineered covalent organic framework with charge-oxygen synergy promotes photocatalytic dipolar [3 + 2] cycloaddition. Chem. Sci.16, 17827–1783 (2025). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Yu, D., Liu, Y. & Che, C.-M. Tungsten catalysed decarboxylative [3 + 2] cycloaddition aromatization: one-pot synthesis of trifluoromethyl-pyrrolo[2,1-a]isoquinolines with visible light irradiation. O. rg. Chem. Front.9, 2779–2785 (2022). [Google Scholar]
- 28.Yi, Z.-Q. et al. Stereoselective synthesis of biology-oriented pentacyclic pyrrolo[2,1-a]isoquinoline scaffolds by photoredox-induced radical annulations. Org. Lett.27, 2197–2202 (2025). [DOI] [PubMed] [Google Scholar]
- 29.Osipov, D. V. et al. Cascade synthesis of pyrrolo[1,2-a]quinolines and pyrrolo[2,1-a]isoquinolines via formal [3 + 2]-cycloaddition of push–pull nitro heterocycles with carbonyl-stabilized quinolinium/isoquinolinium ylides. J. Org. Chem.89, 9816–9829 (2024). [DOI] [PubMed] [Google Scholar]
- 30.Tang, Q. et al. Base-mediated cascade lactonization/1,3-dipolar cycloaddition pathway for the one-pot assembly of coumarin-functionalized pyrrolo[2,1-a]isoquinolines. J. Org. Chem.89, 8420–8434 (2024). [DOI] [PubMed] [Google Scholar]
- 31.Xu, Y.-W., Wang, J., Wang, G. & Zhen, L. Diethyl azodicarboxylate-promoted oxidative [3 + 2] cycloaddition for the synthesis of pyrrolo[2,1-a]isoquinolines. J. Org. Chem.86, 91–102 (2021). [DOI] [PubMed] [Google Scholar]
- 32.Zhang, B.-H. et al. A one-pot synthesis of substituted pyrrolo[2,1-a]isoquinolines via an oxidation/annulation sequence of 2-(3,4-dihydroisoquinolin-2(1H)-yl)malononitriles. J. Org. Chem.90, 7134–7144 (2025). [DOI] [PubMed] [Google Scholar]
- 33.Zheng, K.-L. et al. Acid-mediated intermolecular [3 + 2] cycloaddition toward pyrrolo[2,1-a]isoquinolines: total synthesis of the lamellarin core and lamellarin G trimethyl ether. O. rg. Lett.19, 2262–2265 (2017). [DOI] [PubMed] [Google Scholar]
- 34.Tang, X. et al. Catalyst-free [3 + 2] cyclization of imines and Morita–Baylis–Hillman carbonates: a general route to tetrahydropyrrolo[2,1-a]isoquinolines and dihydropyrrolo[2,1-a]isoquinolines. Org. Chem. Front.4, 2128–2133 (2017). [Google Scholar]
- 35.Nguyen, V.-N. et al. An emerging molecular design approach to heavy-atom-free photosensitizers for enhanced photodynamic therapy under hypoxia. J. Am. Chem. Soc.141, 16243–16248 (2019). [DOI] [PubMed] [Google Scholar]
- 36.Zhang, Y. et al. Recent advances and clinical challenges of phototherapeutic nanoparticles in cancer monotherapy or combination therapy. Coord. Chem. Rev.518, 216069 (2024). [Google Scholar]
- 37.Yuan, X. et al. Phototherapy: progress, challenges, and opportunities. Sci. China Chem.68, 826–865 (2025). [Google Scholar]
- 38.Fan, W., Huang, P. & Chen, X. Overcoming the Achilles’ heel of photodynamic therapy. Chem. Soc. Rev.45, 6488–6519 (2016). [DOI] [PubMed] [Google Scholar]
- 39.Fang, L. et al. Recent advances in strategies to enhance photodynamic and photothermal therapy performance of single-component organic phototherapeutic agents. Adv. Sci.12, 2409157 (2025). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Liu, S. et al. Cationization-enhanced type I and type II ROS generation for photodynamic treatment of drug-resistant bacteria. ACS Nano16, 9130–9141 (2022). [DOI] [PubMed] [Google Scholar]
- 41.Wang, H., Guo, S., Yuan, Q., Li, M. & Tang, Y. Cationic conjugated oligomers for efficient and rapid antibacterial photodynamic therapy via both type I and type II pathways. Chin. J. Chem.42, 61–66 (2024). [Google Scholar]
- 42.Sun, H. et al. Boosting type-I and type-II ROS production of water-soluble porphyrin for efficient hypoxic tumor therapy. Mol. Pharm.20, 606–615 (2023). [DOI] [PubMed] [Google Scholar]
- 43.Li, X., Lee, S. & Yoon, J. Supramolecular photosensitizers rejuvenate photodynamic therapy. Chem. Soc. Rev.47, 1174–1188 (2018). [DOI] [PubMed] [Google Scholar]
- 44.Teng, K.-X. et al. BODIPY-based photodynamic agents for exclusively generating superoxide radical over singlet oxygen. Angew. Chem. Int. Ed.60, 19912–19920 (2021). [DOI] [PubMed] [Google Scholar]
- 45.Dai, J. et al. Triphenylamine-substituted Nile red derivatives with efficient reactive oxygen species generation for robust and broad-spectrum antimicrobial photodynamic therapy and abscess wound healing. Adv. Funct. Mater.35, 2421072 (2025). [Google Scholar]
- 46.Wang, Y.-Y., Liu, Y.-C., Sun, H. & Guo, D.-S. Type I photodynamic therapy by organic–inorganic hybrid materials: from strategies to applications. Coord. Chem. Rev.395, 46–62 (2019). [Google Scholar]
- 47.Zhang, W. et al. Fiber optic-mediated type I photodynamic therapy of brain glioblastoma based on an aggregation-induced emission photosensitizer. Adv. Mater.36, 2410142 (2024). [DOI] [PubMed] [Google Scholar]
- 48.Yang, Z. et al. Recent advances in organic thermally activated delayed fluorescence materials. Chem. Soc. Rev.46, 915–1016 (2017). [DOI] [PubMed] [Google Scholar]
- 49.Mamada, M. et al. Donor-only substituted benzene achieves thermally activated delayed fluorescence. Commun. Chem.7, 212 (2024). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Ni, F., Huang, Y., Qiu, L. & Yang, C. Synthetic progress of organic thermally activated delayed fluorescence emitters via C–H activation and functionalization. Chem. Soc. Rev.53, 5904–5955 (2024). [DOI] [PubMed] [Google Scholar]
- 51.Uoyama, H., Goushi, K., Shizu, K., Nomura, H. & Adachi, C. Highly efficient organic light-emitting diodes from delayed fluorescence. Nature492, 234 (2012). [DOI] [PubMed] [Google Scholar]
- 52.Mamada, M., Hayakawa, M., Ochi, J. & Hatakeyama, T. Organoboron-based multiple-resonance emitters: synthesis, structure–property correlations, and prospects. Chem. Soc. Rev.53, 1624–1692 (2024). [DOI] [PubMed] [Google Scholar]
- 53.Hu, Y. X. et al. Efficient selenium-integrated TADF OLEDs with reduced roll-off. Nat. Photonics16, 803–810 (2022). [Google Scholar]
- 54.Huang, T. et al. Enhancing the efficiency and stability of blue thermally activated delayed fluorescence emitters by perdeuteration. Nat. Photonics18, 516–523 (2024). [Google Scholar]
- 55.Bryden, M. A. & Zysman-Colman, E. Organic thermally activated delayed fluorescence (TADF) compounds used in photocatalysis. Chem. Soc. Rev.50, 7587–7680 (2021). [DOI] [PubMed] [Google Scholar]
- 56.Barman, D. et al. Modulation of donor in purely organic triplet harvesting AIE-TADF photosensitizer for image-guided photodynamic therapy. Small21, 2409533 (2025). [DOI] [PubMed] [Google Scholar]
- 57.Diniz, A. M. et al. TADF-emitting nanoparticles for application as probes in time-resolved imaging and 1O2 photosensitizers. Adv. Opt. Mater.13, 2402063 (2025). [Google Scholar]
- 58.Chen, W. & Song, F. Thermally activated delayed fluorescence molecules and their new applications aside from OLEDs. Chin. Chem. Lett.30, 1717–1730 (2019). [Google Scholar]
- 59.Liu, Z. et al. A dual-targeted theranostic photosensitizer based on a TADF fluorescein derivative. J. Control. Release310, 1–10 (2019). [DOI] [PubMed] [Google Scholar]
- 60.Zhang, J. et al. Exploration of Thermally Activated Delayed Fluorescence (TADF)-Based Photoredox Catalyst To Establish the Mechanisms of Action for Photodynamic Therapy. ACS Nano17, 23430–23441 (2023). [DOI] [PubMed] [Google Scholar]
- 61.Ni, F., Li, N., Zhan, L. & Yang, C. Organic thermally activated delayed fluorescence materials for time-resolved luminescence imaging and sensing. Adv. Opt. Mater.8, 1902187 (2020). [Google Scholar]
- 62.Fang, F. et al. Thermally activated delayed fluorescence material: an emerging class of metal-free luminophores for biomedical applications. Adv. Sci.8, 2102970 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 63.Zheng, K. et al. Molecular iodine-mediated formal [2+1+1+1] cycloaddition access to pyrrolo[2,1-a]isoquinolines with DMSO as the methylene source. Chem. Commun.54, 11897–11900 (2018). [DOI] [PubMed] [Google Scholar]
- 64.Zhuang, S.-Y. et al. I2-DMSO-mediated N–H/α-C(sp3)–H difunctionalization of tetrahydroisoquinoline: formal [2 + 2 + 1] annulation for the construction of pyrrolo[2,1-a]isoquinoline derivatives. Org. Lett.24, 2858–2862 (2022). [DOI] [PubMed] [Google Scholar]
- 65.Zhuang, S.-Y. et al. I2-DMSO mediated multicomponent [3+2] annulation reaction: an approach to pyrrolo[2,1-a]isoquinoline derivatives with a quaternary center. Org. Lett.24, 8573–8577 (2022). [DOI] [PubMed] [Google Scholar]
- 66.Tang, Y.-X. et al. Unlocking oxidative cross-coupling between four nucleophiles: synthesis of spiropyrrolo[2,1-a]isoquinolines. Org. Lett.28, 74–80 (2026). [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Description of Additional Supplementary Files
Data Availability Statement
The X-ray crystallographic coordinates for structures reported in this article have been deposited at the Cambridge Crystallographic Data Centre (CCDC), under deposition numbers CCDC 2505511. These data can be obtained free of charge from either Supplementary Data 1 or The Cambridge Crystallographic Data Center via https://www.ccdc.cam.ac.uk/ structures/. Source data for ROS generation and cytotoxicity assays (light/dark) are provided in Supplementary Data 4. NMR spectra for all synthesized compounds are provided in Supplementary Data 5. All other data supporting the findings of the study, including experimental procedures and compound characterization, UV–vis absorption spectrometry, fluorescence and phosphorescence spectrometry, are available within the paper and the Supplementary Information. Correspondence and requests for materials should be addressed to K.L.Z.; all data are available from the corresponding author upon request.
